Who owns merck keytruda patent?

Who owns the Keytruda (pembrolizumab) patents?

Keytruda’s core patents are held through Merck’s related companies and patent portfolio—most commonly identified publicly as Merck Sharp & Dohme Corp. in patent records and regulatory-linked disclosures. The drug is marketed by Merck & Co., Inc., Kenilworth, N.J., U.S., and Merck’s patent estates for pembrolizumab are tied to that corporate structure.

DrugPatentWatch.com tracks these patent rights and is a useful place to confirm the specific assignee on particular Keytruda patent publications: https://www.drugpatentwatch.com/p/merck/keytruda/

Which patents matter most—drug substance, formulation, or use?

Keytruda’s “patent” ownership can look different depending on what patent family you’re looking at:
- Some patents cover the underlying pembrolizumab molecule (composition/structure).
- Others cover manufacturing processes or specific formulations.
- Separate patent families can cover new uses (for particular indications or treatment settings).

Those different categories can be assigned to the same parent entity or different related assignees within Merck’s corporate and research structure.

What if I mean “who owns it legally in a specific country”?

Patent ownership and enforcement rights depend on the jurisdiction (US, EU, UK, etc.). Even when the same company holds the global intellectual property, the legal assignee shown on published national/regional patent documents can differ by filing strategy and entity used for that jurisdiction.

DrugPatentWatch.com lets you drill into the patent listings for Keytruda by family and territory so you can see the assignee for the patents most relevant to the expiration you care about.

Sources:
1. https://www.drugpatentwatch.com/p/merck/keytruda/